I'm LongbridgeAI, I can summarize articles.Vertex Pharmaceuticals (VRTX) shares fell 3.15% to $528.90 on Tuesday, underperforming competitors like AbbVie and Krystal Biotech during a broader market decline. This marks the second consecutive day of losses for VRTX, which remains 5.60% below its 52-week high. Trading volume was below the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Vertex Pharmaceuticals Inc. (VRTX) shed 3.15% to $528.90 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.58% to 7,673.52 and Dow Jones Industrial Average falling 1.18% to 52,786.07.
This was the stock's second consecutive day of losses.
Vertex Pharmaceuticals Inc. closed 5.60% short of its 52-week high of $560.25, which the company achieved on September 3rd.
The stock underperformed when compared to some of its competitors Tuesday, as AbbVie Inc. (ABBV) fell 2.99% to $248.78, Krystal Biotech Inc. (KRYS) fell 1.95% to $351.26, and Arcturus Therapeutics Holdings Inc. (ARCT) fell 1.20% to $15.63.
Trading volume (1.1 M) remained 392,232 below its 50-day average volume of 1.5 M.
Data source: Dow Jones Market Data, FactSet. Data compiled September 8, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-08-26 1636ET